Table 1.

Clinical data and the activity of caspase 3 and the concentration of DHA in the serum of venous cord blood in patients from both analyzed groups.

Variable	Median	Min–max	95% CI	P(U) value
Maternal age (y)
DHA group (n = 28)	25,5	19–39	25,2–26,7	0,5399
Control group (n = 50)	26	18–35	24,2–26,8
Gestational age (w)
DHA group (n = 28)	39,5	37,8–41,2	39,26–39,64	0,2151
Control group (n = 50)	39,20	37,6–41
Birth weight (g)
DHA group (n = 28)	3675	2990–4350	3589–3760	0,8815
Control group (n = 50)	3785	3170–4400	3725–3844
Placenta weight (g)
DHA group (n = 28)	510	440–650	497–522	0,0071
Control group (n = 50)	530	410–610	522–537
Apgar score at 5 minutes (p)
DHA group (n = 28)	10	8–10	9,87–10,13	1,0000
Control group (n = 50)	10	7–10	9,88–10,12
Caspase 3 activity (μmol pNa/min/mL)
DHA group (n = 28)	0,053	0,0084–0,048	0,0511–0,0549	0,0001
Control group (n = 50)	0,059	0,0047–0,049	0,0582–0,0598
Cord DHA (ng/μL)
DHA group (n = 28)	3,86	3,54–4,13	3,83–3,89	0,0001
Control group (n = 50)	3,61	3,49–3,79	3,60–3,62